FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178464379> ?p ?o ?g. }

• W3178464379 endingPage "2747" @default.
• W3178464379 startingPage "2738" @default.
• W3178464379 abstract "Abstract Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and safety of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade (AtezoBev) was assessed in 20 patients with advanced and unresectable MPeM with progression or intolerance to prior platinum–pemetrexed chemotherapy. The primary endpoint of confirmed objective response rate per RECISTv1.1 by independent radiology review was 40% [8/20; 95% confidence interval (CI), 19.1–64.0] with median response duration of 12.8 months. Six (75%) responses lasted for &gt;10 months. Progression-free and overall survival at one year were 61% (95% CI, 35–80) and 85% (95% CI, 60–95), respectively. Responses occurred notwithstanding low tumor mutation burden and PD-L1 expression status. Baseline epithelial–mesenchymal transition gene expression correlated with therapeutic resistance/response (r = 0.80; P = 0.0010). AtezoBev showed promising and durable efficacy in patients with advanced MPeM with an acceptable safety profile, and these results address a grave unmet need for this orphan disease. Significance: Efficacy of atezolizumab and bevacizumab vis-à-vis response rates and survival in advanced peritoneal mesothelioma previously treated with chemotherapy surpassed outcomes expected with conventional therapies. Biomarker analyses uncovered epithelial–mesenchymal transition phenotype as an important resistance mechanism and showcase the value and feasibility of performing translationally driven clinical trials in rare tumors. See related commentary by Aldea et al., p. 2674. This article is highlighted in the In This Issue feature, p. 2659" @default.
• W3178464379 created "2021-07-19" @default.
• W3178464379 creator A5002024602 @default.
• W3178464379 creator A5002142766 @default.
• W3178464379 creator A5003827387 @default.
• W3178464379 creator A5006246174 @default.
• W3178464379 creator A5009153348 @default.
• W3178464379 creator A5010092165 @default.
• W3178464379 creator A5011930622 @default.
• W3178464379 creator A5012619170 @default.
• W3178464379 creator A5014312007 @default.
• W3178464379 creator A5014577763 @default.
• W3178464379 creator A5023336828 @default.
• W3178464379 creator A5024796100 @default.
• W3178464379 creator A5027712976 @default.
• W3178464379 creator A5028085268 @default.
• W3178464379 creator A5031815841 @default.
• W3178464379 creator A5032970786 @default.
• W3178464379 creator A5033680753 @default.
• W3178464379 creator A5033798832 @default.
• W3178464379 creator A5034467403 @default.
• W3178464379 creator A5035273559 @default.
• W3178464379 creator A5039834119 @default.
• W3178464379 creator A5040791524 @default.
• W3178464379 creator A5041329154 @default.
• W3178464379 creator A5043450833 @default.
• W3178464379 creator A5043534982 @default.
• W3178464379 creator A5048679191 @default.
• W3178464379 creator A5057814118 @default.
• W3178464379 creator A5062181429 @default.
• W3178464379 creator A5072196458 @default.
• W3178464379 creator A5074948975 @default.
• W3178464379 creator A5076432829 @default.
• W3178464379 creator A5079242757 @default.
• W3178464379 creator A5080487639 @default.
• W3178464379 creator A5088853428 @default.
• W3178464379 date "2021-07-14" @default.
• W3178464379 modified "2023-10-18" @default.
• W3178464379 title "Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma" @default.
• W3178464379 cites W1970295903 @default.
• W3178464379 cites W1993319780 @default.
• W3178464379 cites W2055698606 @default.
• W3178464379 cites W2060760531 @default.
• W3178464379 cites W2066343477 @default.
• W3178464379 cites W2088571368 @default.
• W3178464379 cites W2096957631 @default.
• W3178464379 cites W2118880233 @default.
• W3178464379 cites W2124680669 @default.
• W3178464379 cites W2215044613 @default.
• W3178464379 cites W2226221856 @default.
• W3178464379 cites W2266849806 @default.
• W3178464379 cites W2616456558 @default.
• W3178464379 cites W2760942750 @default.
• W3178464379 cites W2791328450 @default.
• W3178464379 cites W2805302875 @default.
• W3178464379 cites W2898156664 @default.
• W3178464379 cites W2899347223 @default.
• W3178464379 cites W2916532294 @default.
• W3178464379 cites W2924341172 @default.
• W3178464379 cites W2961145036 @default.
• W3178464379 cites W2977339506 @default.
• W3178464379 cites W2980682287 @default.
• W3178464379 cites W2981442353 @default.
• W3178464379 cites W3003992007 @default.
• W3178464379 cites W3009724004 @default.
• W3178464379 cites W3011615845 @default.
• W3178464379 cites W3024631130 @default.
• W3178464379 cites W3025022288 @default.
• W3178464379 cites W3111976262 @default.
• W3178464379 cites W3122627530 @default.
• W3178464379 doi "https://doi.org/10.1158/2159-8290.cd-21-0331" @default.
• W3178464379 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8563380" @default.
• W3178464379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34261675" @default.
• W3178464379 hasPublicationYear "2021" @default.
• W3178464379 type Work @default.
• W3178464379 sameAs 3178464379 @default.
• W3178464379 citedByCount "32" @default.
• W3178464379 countsByYear W31784643792021 @default.
• W3178464379 countsByYear W31784643792022 @default.
• W3178464379 countsByYear W31784643792023 @default.
• W3178464379 crossrefType "journal-article" @default.
• W3178464379 hasAuthorship W3178464379A5002024602 @default.
• W3178464379 hasAuthorship W3178464379A5002142766 @default.
• W3178464379 hasAuthorship W3178464379A5003827387 @default.
• W3178464379 hasAuthorship W3178464379A5006246174 @default.
• W3178464379 hasAuthorship W3178464379A5009153348 @default.
• W3178464379 hasAuthorship W3178464379A5010092165 @default.
• W3178464379 hasAuthorship W3178464379A5011930622 @default.
• W3178464379 hasAuthorship W3178464379A5012619170 @default.
• W3178464379 hasAuthorship W3178464379A5014312007 @default.
• W3178464379 hasAuthorship W3178464379A5014577763 @default.
• W3178464379 hasAuthorship W3178464379A5023336828 @default.
• W3178464379 hasAuthorship W3178464379A5024796100 @default.
• W3178464379 hasAuthorship W3178464379A5027712976 @default.
• W3178464379 hasAuthorship W3178464379A5028085268 @default.
• W3178464379 hasAuthorship W3178464379A5031815841 @default.
• W3178464379 hasAuthorship W3178464379A5032970786 @default.
• W3178464379 hasAuthorship W3178464379A5033680753 @default.

• next